Acute hepatitis after riluzole administration

Journal of Hepatology

Volumn 30, Issue 3, 1999, Pages 527-530

  Remy, André Jean ^a   Camu, William ^b   Ramos, Jeanne ^b   Blanc, Pierre ^a   Larrey, Dominique ^a  

^a HÔPITAL SAINT ELOI   (France)

^b GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Drug induced hepatitis; Microvesicular steatosis; Riluzole

Indexed keywords

RILUZOLE;

ACUTE HEPATITIS; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CASE REPORT; CHOLESTASIS; DRUG INDUCED DISEASE; FEMALE; HUMAN; INFLAMMATORY INFILTRATE; LIVER BIOPSY; LIVER INJURY; PRIORITY JOURNAL; STEATOSIS; TOXIC HEPATITIS;

EID: 0032995109     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80115-9     Document Type: Article

References (19)

1. Bensimon G, Lacomblez L. Meininger V and the Amyotrophic Lateral Sclerosis/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 330:1993;585-591.
2. Lacomblez L, Bensimon G, Leigh PN, Guillet P. Meininger V and the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 347:1996;1425-1431.
3. McKee P, Fuller GN, Stevens D, McRae K, Burgerman RS, Rogawski MA, et al. Riluzole in amyotrophic lateral sclerosis: comments. N Engl J Med. 331:1993;272-275.
4. Riluzole for amyotrophic lateral sclerosis. Med Lett Drugs Ther. 37:1995;113-114.
5. Nightingale SL. From the Food and Drug Administration. JAMA. 274:1995;292.
6. Criteria of drug-induced liver disorders: report from international consensus meeting. J Hepatol. 11:1990;272-276.
7. Biour M, Poupon R, Grange JD, Cazouillères O, Levy VG, Jaillon P. Hépatotoxicité des médicaments: 10ème mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroenterol Clin Biol. 21:1997;660-696.
8. Pessayrc D. Physiopathologie des hépatopathies médicamenteuses. Gastroenterol Clin Biol. 17:1993;H3-H17.
9. Stricker BHCH. Drug-induced Hepatic Injury, 5th ed. 1992;Elsevier, Amsterdam.
10. Genève J, Larrey D, Pessayre D, Benhamou JP. Structure tricyclique des médicaments et hépatotoxicité Gastroenterol Clin Biol. 11:1987;242-249.
11. Bjorge SM, Baillie TA. Inhibition of medium chain-fatty acid beta-oxidation in vitro by valproic acid and its unsatured metabolite, 2-n-propyl-4-pentenoic acid. Biochem Biophys Res Commun. 132:1985;245-252.
12. Genève J. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this non-steroidal anti-inflammatory drug. J Pharmacol Exp Ther. 242:1987;1137-1142.
13. Le Dinh T. Amineptine, a tricyclic antidepressant, inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther. 247:1989;745-750.
14. Frénaux E. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in humans. Possible role in microvesicular steatosis induced by this antibiotic. Hepatology. 8:1988;1062-1065.
15. Deschamps D, de Beco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexilline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic lesions. Hepatology. 19:1994;948-961.
16. Bacq Y. Stéatose hépatique aiguë gravidique. Gastroenterol Clin Biol. 21:1997;109-115.
17. Treem WR, Witzleben CA, Piccoli DA, Stanley CA, Hale DE, Coates PM, et al. Medium-chain and long-chain acyl CoA dehydrogenase deficiency: clinical, pathologic and ultrastructural differentiation from Reye's syndrome. Hepatology. 6:1986;1270-1278.
18. Grimbert S, Fromenty B, Fisch C, Letteron P, Berson A, Durand-Schneider AM, et al. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. Hepatology. 17:1993;628-637.
19. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol. 26:(suppl 1):1997;13-22.